#dive

Related news

Neurotrope stock tumbles again on Alzheimer's data

Published: 20/07/2017

Sea-derived bryostatin-1 still isn't quite hitting the spot for Neurotrope in Alzheimer's disease. Read more

Source: www.biopharmadive.com
Takeda shuffles sales force as restructuring continues

Published: 19/07/2017

The Japanese pharma has axed and relocated hundreds of sales positions as it continues to rejigger its portfolio. Read more

Source: www.biopharmadive.com
PhRMA finally talks drug pricing in new campaign

Published: 19/07/2017

The trade group's newest campaign aims to tackle frequently asked drug cost questions, while also defending pharma's role in pricing decisions. Read more

Source: www.biopharmadive.com

Positive triple combo data sets up Vertex for big growth

Published: 19/07/2017

The new data on its cystic fibrosis treatments lifted shares more than 20%, adding billions to the company's market capitalization. Read more

Source: www.biopharmadive.com
Abeona set to fly into Phase 3 after FDA chat

Published: 19/07/2017

Following FDA guidance, Abeona is scooting EB-101 straight into Phase 3 for "butterfly disease." Read more

Source: www.biopharmadive.com
Sarepta, BioMarin iron out Exondys 51 patent terms

Published: 18/07/2017

The deal exchanges upfront, milestone and royalty payments for a patent estate covering exon-skipping therapies. Read more

Source: www.biopharmadive.com

Novartis upbeat on I/O despite lagging behind competitors

Published: 18/07/2017

The big pharma touted prospects for its CAR-T therapy and its immuno-oncology pipeline during a second quarter earnings call. Read more

Source: www.biopharmadive.com
Patient centricity's challenges and opportunities

Published: 18/07/2017

Can pharma companies truly be patient-centric when they’re so far from the patient? Read more

Source: www.biopharmadive.com
J&J: Remicade holding up better than expected

Published: 18/07/2017

While second quarter sales slipped 14% for the anti-inflammatory drug, the big pharma noted that biosimilars played a muted role in that decline. Read more

Source: www.biopharmadive.com

Puma granted broad label for neratinib after FDA OK

Published: 18/07/2017

The biotech gets a green light for its breast cancer drug, despite serious side effects and concerns raised by an advisory committee. Read more

Source: www.biopharmadive.com
CymaBay touts positive seladelpar liver results

Published: 18/07/2017

Results from a lower dose study showed efficacy without the liver toxicity issues, driving up shares of the stock. Read more

Source: www.biopharmadive.com
New data from Alzheon shows long-term benefit for Alzheimer's

Published: 17/07/2017

APOE4 homozygotes who received higher doses of Alzheon's candidate over multiple years had "sustained cognitive and functional benefits." Read more

Source: www.biopharmadive.com

New data from Alzheon's shows long-term benefit for Alzheimer's

Published: 17/07/2017

Patients with two copies of an Alzheimer's risk factor who received higher doses of Alzheon's candidate over multiple years had "sustained cognitive and functional benefits ... Read more

Source: www.biopharmadive.com
Alzheimer's disease: What you need to know

Published: 17/07/2017

The debilitating neurological condition is becoming a bigger burden on society as the population ages. Here's a look at the science and trends shaping Alzheimer's disease drug development ... Read more

Source: www.biopharmadive.com
5 trends shaping Alzheimer's drug development

Published: 17/07/2017

Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned. Read more

Source: www.biopharmadive.com

Genentech BD: Alzheimer's continues to be a priority

Published: 17/07/2017

Genentech's Tom Zioncheck sat down with BioPharma Dive to talk about the big biotech's work in Alzheimer's disease. Read more

Source: www.biopharmadive.com
What do we know about the amyloid theory for Alzheimer's?

Published: 17/07/2017

A growing knowledge of the science behind the disease is allowing researchers to better test potential therapies. Read more

Source: www.biopharmadive.com
Alzheimer's drug developers still hoping for a homer

Published: 17/07/2017

The unmet need presented by the ever-growing patient population coupled with better science has the Alzheimer's disease pipeline filling up. Read more

Source: www.biopharmadive.com

Valeant unloads Obagi in latest sell-off

Published: 17/07/2017

The beleaguered company continues to sell assets in an effort to reduce debt and move the company forward. Read more

Source: www.biopharmadive.com
First gene therapy could hit the market in January

Published: 17/07/2017

Spark Therapeutics has landed a January user fee goal date for its gene therapy for a rare form of blindness. Read more

Source: www.biopharmadive.com
Clinical hold still in effect for Repros' oral drug

Published: 17/07/2017

The drugmaker is now weighing a shift in focus to its vaginal drug delivery program for Proellex. Read more

Source: www.biopharmadive.com

Related Hashtags

Most read

FACEBOOK

Facebook

Place your ad here
Loading...